Back to homepage

Tag "bevacizumab"

Anti-angiogenesis therapy, synthetic lethality, and checkpoint inhibition in ovarian cancer: state of the science and novel combinations

Authors: Marisa C Liu MD, MPH, Krishnansu S Tewari MD

This review summarizes studies related to anti-angiogenic treatment, synthetic lethality, and checkpoint inhibition of ovarian cancer and additionally novel combinations that offer a veritable therapeutic matrix for clinicians to choose from.

More

The role of anti-vascular endothelial growth factor (anti-VEGF) in the management of proliferative diabetic retinopathy

Authors: Yue Zhao MD, Rishi P Singh MD

This review discusses recent clinical trials and guidelines for anti-VEGF use in proliferative diabetic retinopathy.

More

Prognostic and predictive factors of eribulin efficacy in heavily pretreated patients affected by metastatic breast cancer: correlation with tumor biology and previous therapies

Authors: Sabrina Rossi, Alessandra Cassano, Antonia Strippoli, Giovanni Schinzari, Ettore D’Argento, Michele Basso, Carlo Barone

This retrospective study looks to find specific predictive criteria related to patient or tumor characteristics in order to select patients that might benefit the most from eribulin and define the correct treatment sequence.

More

Glioblastoma treatment patterns, survival, and healthcare resource use in real-world clinical practice in the USA

Authors: Allicia C Girvan, Gebra C Carter, Li Li, Anna Kaltenboeck, Jasmina Ivanova, Maria Koh, Jessi Stevens, Eleanor Hayes-Larson, Michael M Lahn

Glioblastoma (GB) treatment remains challenging because of recurrence and poorly defined treatment options after first-line therapy. To better understand real-world application of treatment paradigms and their impact on outcomes, the authors describe patterns of GB treatment, outcomes, and use of cancer-related healthcare resource in the USA.

More